Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: David Cathcart who wrote (638)	2/6/1998 12:55:00 PM
From: Biomaven	Respond to of 1826

David, Thanks for your response. I think you are right - the "new" article refers to the early part of the Phase I, and their prediction of a MTD of 8mg/m^2/day was fortunately too pessimistic. This means they are using doses roughly triple those in the article and so hopefully are reaching levels where effectiveness seems likely. <<Peak plasma levels have ranged from 31-974 ng/ml which approach levels that induce cytotoxicity in vitro and have been associated with toxicity in dogs.>> So now this article starts to look like good news to me: the current doses being used are nearly triple those which gave plasma levels "approaching" cytotoxic levels in vitro. Peter